About us

Leadership team

Our leadership team brings together the expertise across the full clinical research landscape. From CMC, drug labeling, radiopharmaceutical development, and regulatory strategy to clinical execution and business leadership.

Prof. Go van Dam, MD, PhD

CEO & Founder

A pioneer in the optical imaging field with ground breaking research to his name.

Co-founder Prof. Van Dam, surgeon oncologist and professor of Surgery at Groningen University, trained at Harvard, the Mayo Clinic and NCI.

He has published the 1st in-human application of targeted fluorescence imaging in 2011 (Nature Medicine) and published more than 140 papers predominantly on the subject of clinical translation of innovative targeted optical molecular imaging.

Ari Aminetzah, MBA, PhD candidate

CBO & Founder

A life science veteran with over 25 years of international experience in the industry.

Co-founder Ari is a senior life sciences veteran, with executive business development roles among others at J&J and Crucell, a vaccine company sold to J&J for $2.7B. Ari also serves as advisor to the Ministry of Economic Affairs in the Netherlands, McKinsey & Co and multiple ventures in Europe and the USA.

Tessa Aminetzah

Senior VP Commercial Operations

A creative and analytical brand storyteller with an international business background.

Tessa has a double degree in International Business and Management both from Eastern Kentucky University and Avans Hogeschool in Breda, the Netherlands. She has presented at the Academy of Business Research conference and excels in strengthening marketing efforts of startup ventures both in Europe and the USA.

Maarten Brom, PhD

VP Technology Assessment

A seasoned scientist, specialised in chemistry and nuclear imaging techniques.

Maarten is a senior radiochemist with a focus on the development and characterization of radiolabeled and fluorescent tracers.

He has had various roles as a scientist at the Radboud University Medical Center in Nijmegen, The Netherlands, where his research in in vivo imaging techniques had a strong translational character.

Marjolein Bolhuis

VP People & Culture

A people-focused and entrepreneurial professional with a passion for building meaningful connections, fostering inclusive cultures, and enabling people and teams to thrive. Marjolein studied Dutch Labor Law & Strategic Human Resources.

She has extensive leadership experience from healthcare and hospitality, with a background in organizational development and people-centered leadership.

Babette ten Bosch

Financial Advisor

Experienced financial advisor to TRACER. She gained broad experience in audit, restructuring, consulting, mergers and acquisitions, and financial management at various corporate organizations and in small and medium-sized companies.

This enables her to make a connection between the clinical studies (‘business’) and the required quality of the financial organization (‘finance’) required to enable TRACER to execute its strategy.

Supported by high-profile Key Opinion Leaders

TRACER is advised by a forum composed of distinguished Key Opinion Leaders (KOLs) with recognized expertise across early-phase clinical research, clinical imaging techniques, commercial strategy, and pioneering scientific innovation. This forum provides strategic guidance, scientific oversight, and expert evaluation to ensure our research and development efforts remain rigorous, forward-looking, and aligned with the evolving needs of patients and the industry.

Christopher P. Leamon, Ph.D.

Radiopharmaceutical executive

Dr. Leamon is the former Chief Scientific Officer at Fusion Pharmaceuticals where he led the Discovery efforts for novel actinium-225 based cancer targeted therapeutics, including 225Ac-FPI-2265 (ALPHA-BREAK phase 2/3 trial)

and helped facilitate the Company’s 2024 $2.4B acquisition by Astra Zeneca. Prior to Fusion Dr. Leamon was a scientific co-founder and Vice President of R&D at Endocyte, Inc. spanning 23 years of organization building to develop tissue-targeted agents for cancer, inflammation and polycystic kidney disease. These efforts included radiopharmaceutical imaging (SPECT and PET), radioligand therapy (RLT; targeted alpha and beta therapy), targeted chemotherapeutics (SMDC; ADC), immune (CAR-T) and gene therapy projects. Development programs at Endocyte included etarfolatide (99mTc-EC20; phase 3 for companion imaging), vintafolide (a folate-vinca therapeutic; PROCEED phase 3 trial) and Pluvicto (177Lu-PSMA-617; VISION phase 3 trial) until the Company’s 2018 $2.1B acquisition by Novartis. Prior to Endocyte he was a leader in targeted drug delivery research at both GlaxoSmithKline, Inc. and Ionis Pharmaceuticals, Inc.
Dr. Leamon received an ACS-certified B.S. degree in Chemistry from Baldwin Wallace University (1988) and a Ph.D. in Chemistry from Purdue University (1993). He has spent over 36 years working in the drug delivery field and is also credited for conducting groundbreaking experiments in folate-targeted technology as well as for exemplifying this novel therapeutic approach for treating cancer. Dr. Leamon has published over 90 articles and is an inventor on 70 issued or submitted patents involving drug targeting. In 2015 he also received the American Chemical Society, George and Christine Sosnovsky Award for Cancer Research.
Dr. Leamon is currently serving on the board of directors of three privately held biotechnology companies, including EndPath Radiotherapeutics (also joining as CSO in June 2026), Ironfist Therapeutics and Inversion Therapeutics.

Ben Feringa (NL)

Professor of Molecular Sciences University of Groningen

Prof. Ben L. Feringa is a Nobel Prize-winning chemist (2016) known for groundbreaking work on molecular motors, switches, and photopharmacology.

Jason Lewis (UK)

Emily Tow Chair Memorial Sloan Kettering Cancer Center

Prof. Jason S. Lewis is a global leader in radiochemistry and molecular imaging. His research focuses on developing radiopharmaceuticals and multimodal imaging agents for clinical translation.

Rudie Dierckx (BE)

Professor Nuclear Medicine University Medical Center Groningen

Prof. Dr. Rudi Dierckx is a nuclear medicine expert with a career spanning clinical innovation, academic leadership, and international quality standards. He led departments at UMCG and served as EANM president.

Careers at TRACER

Join a team where you’ll have the opportunity to apply your knowledge and skills to the development of (radio)pharmaceuticals that will shape the medicines of the future.

Careers